Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Approval after phase I: ceritinib runs the three-minute mile.

Literature DB >> 24789171

Approval after phase I: ceritinib runs the three-minute mile.

Bruce A Chabner¹.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2014 PMID： 24789171 PMCID： PMC4041677 DOI： 10.1634/theoncologist.2014-0143

Source DB: PubMed Journal: Oncologist ISSN： 1083-7159

× No keyword cloud information.

4 in total

1. The oncologic four-minute mile.

Authors: B A Chabner
Journal: Oncologist Date: 2001

2. Ceritinib in ALK-rearranged non-small-cell lung cancer.

Authors: Alice T Shaw; Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Juergen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Yvonne Y Lau; Meredith Goldwasser; Anthony L Boral; Jeffrey A Engelman
Journal: N Engl J Med Date: 2014-03-27 Impact factor: 91.245

Review 3. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.

Authors: Sai-Hong Ignatius Ou; Cynthia Huang Bartlett; Mari Mino-Kenudson; Jean Cui; A John Iafrate
Journal: Oncologist Date: 2012-09-18

4. Cancer-drug discovery and cardiovascular surveillance.

Authors: John D Groarke; Susan Cheng; Javid Moslehi
Journal: N Engl J Med Date: 2013-11-01 Impact factor: 91.245

4 in total

15 in total

1. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.

Authors: Gideon M Blumenthal; Stella W Karuri; Hui Zhang; Lijun Zhang; Sean Khozin; Dickran Kazandjian; Shenghui Tang; Rajeshwari Sridhara; Patricia Keegan; Richard Pazdur
Journal: J Clin Oncol Date: 2015-02-09 Impact factor: 44.544

2. Defining a new role for the National Cancer Institute cooperative groups: more science, fewer trials.

Authors: Bruce A Chabner
Journal: Oncologist Date: 2014-10-17

3. Breakthrough Drugs and Turtle Soup.

Authors: Bruce A Chabner
Journal: Oncologist Date: 2015-07-16

4. Twenty Years with Personalized Medicine: Past, Present, and Future of Individualized Pharmacotherapy.

Authors: Jan Trøst Jørgensen
Journal: Oncologist Date: 2019-04-02

5. Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.

Authors: Todd Hembrough; Wei-Li Liao; Christopher P Hartley; Patrick C Ma; Vamsidhar Velcheti; Christopher Lanigan; Sheeno Thyparambil; Eunkyung An; Manish Monga; David Krizman; Jon Burrows; Laura J Tafe
Journal: Clin Chem Date: 2015-11-19 Impact factor: 8.327

Approval after phase I: ceritinib runs the three-minute mile.

1. The oncologic four-minute mile.

2. Ceritinib in ALK-rearranged non-small-cell lung cancer.

Review 3. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.

4. Cancer-drug discovery and cardiovascular surveillance.

1. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.

2. Defining a new role for the National Cancer Institute cooperative groups: more science, fewer trials.

3. Breakthrough Drugs and Turtle Soup.

4. Twenty Years with Personalized Medicine: Past, Present, and Future of Individualized Pharmacotherapy.

5. Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.

Review 6. Phase I trials as valid therapeutic options for patients with cancer.

7. Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib.

8. International Clinical Trials Day 2014-ancient and modern needs.

9. Regarding "Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies".

Review 10. Second- and third-generation ALK inhibitors for non-small cell lung cancer.